Last reviewed · How we verify
VERT-002
At a glance
| Generic name | VERT-002 |
|---|---|
| Also known as | PFL-002 |
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VERT-002 CI brief — competitive landscape report
- VERT-002 updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI